TOTUM-63

Initiation of the pivotal late stage development phase of TOTUM-63, with Nestlé Health Science

Learn more

VALBIOTIS

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63

Learn more

TOTUM-63

VALBIOTIS announces positive results from the Phase II clinical study of TOTUM-63.

Read the press release

Prediabetes

VALBIOTIS publishes the first prediabetes market data.

Read the press release

TOTUM-63

VALBIOTIS succeeds in the industrial production of TOTUM-63, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group.

Read the press release
S c r o l l

Products

.01

TOTUM-63

Prediabetes
• Reduction of the risk of type 2 diabetes
• Positive Phase II clinical study

Learn more

.02

TOTUM-070

Mild to moderate hypercholesterolemia
• Reduction of blood LDL-cholesterol
• Clinical Phase I/II positive

Learn more

.03

TOTUM-448

Non-alcoholic hepatic steatosis
• Reduction of steatosis, risk condition for NASH

Learn more

.04

TOTUM-854

Arterial hypertension
- Reduces hypertension, a risk factor for cardiovascular diseases

Learn more

Key figures

Patent families filed

4
All exploitation rights obtained

Employees

> 35
75% in R&D

Listed on the Stock Exchange

2017
Euronext Growth

Our last posts

11.02.2020

Investor meetings – Portzamparc

En savoir plus
28.01.2020

Biomed Event

En savoir plus
16.10.2019

French Society of Financial Analysts (SFAF)

En savoir plus
14.10.2019

European Large & Midcap Event

En savoir plus
Voir tous

VALBIOTIS© listed on the Stock Exchange

Learn more

Follow us!

See more